Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Recent oral antidiabetic therapy].

C Herbaut1

  • 1Service de Médecine Interne/Endocrino-diabétologie, C.H.U. Brugmann, Bruxelles.

Revue Medicale De Bruxelles
|October 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Cytochemical and ultrastructural study of oogenesis inLithobius forficatus L. (Myriapoda, Chilopoda). Evolution of cellular components].

Wilhelm Roux' Archiv fur Entwicklungsmechanik der Organismen·2017
Same author

Pearl formation: persistence of the graft during the entire process of biomineralization.

Marine biotechnology (New York, N.Y.)·2006
Same author

[Omega-3 and health].

Revue medicale de Bruxelles·2006
Same author

Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects.

Research communications in molecular pathology and pharmacology·1999
Same author

Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension.

The American journal of medicine·1992
Same author

[Lipoprotein (a): a new cardiovascular risk factor].

Revue medicale de Bruxelles·1991

Improving type 2 diabetes management involves new medications like thiazolidinediones and glinides. These drugs, often combined with other treatments, help lower HbA1c levels and improve diabetic equilibrium, reducing microvascular complications.

Area of Science:

  • Endocrinology
  • Pharmacology

Context:

  • Type 2 diabetes mellitus (T2DM) management remains challenging, with many patients failing to achieve target HbA1c levels.
  • Microvascular complications are linked to poor diabetic equilibrium.

Purpose:

  • To review current and emerging pharmacologic strategies for improving glycemic control in T2DM.
  • To highlight new drug classes and combination therapies available in Belgium.

Summary:

  • Thiazolidinediones (e.g., pioglitazone, rosiglitazone) act as PPARgamma agonists, enhancing insulin sensitivity and reducing HbA1c.
  • Glinides (e.g., repaglinide) improve postprandial glycemic control.
  • Enhanced patient compliance can be achieved through once-daily dosing regimens (e.g., glimepiride, gliclazide MR).
  • Fixed-dose combinations (e.g., glibenclamide + metformin, rosiglitazone + metformin) offer simplified therapeutic options.

Related Experiment Videos

Impact:

  • These advancements provide clinicians with diverse options to optimize T2DM treatment.
  • Improved glycemic control is expected to reduce the incidence of long-term diabetic complications.